相似文献
1
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
J Clin Microbiol. 2006 Oct;44(10):3781-3. doi: 10.1128/JCM.01249-06.
2
Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
Clin Vaccine Immunol. 2007 Aug;14(8):1053-5. doi: 10.1128/CVI.00173-07. Epub 2007 Jun 27.
3
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.
4
A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
Virol J. 2012 Nov 23;9:287. doi: 10.1186/1743-422X-9-287.
5
Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
J Med Virol. 2012 Sep;84(9):1408-14. doi: 10.1002/jmv.23325.
6
Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
J Med Virol. 2013 Jun;85(6):1077-84. doi: 10.1002/jmv.23546.
7
The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
J Med Virol. 2010 Mar;82(3):407-14. doi: 10.1002/jmv.21721.
8
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
AIDS. 2004 May 21;18(8):1213-6. doi: 10.1097/00002030-200405210-00019.
9
Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey.
J Infect Dis. 1998 Dec;178(6):1776-8. doi: 10.1086/314498.
10
Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Emerg Microbes Infect. 2017 Jun 7;6(6):e43. doi: 10.1038/emi.2017.29.
引用本文的文献
1
The seroprevalence of adenoviruses since 2000.
Emerg Microbes Infect. 2025 Dec;14(1):2475831. doi: 10.1080/22221751.2025.2475831. Epub 2025 Mar 17.
2
Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021.
Intervirology. 2024;67(1):19-39. doi: 10.1159/000538233. Epub 2024 Mar 8.
3
Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines.
PLoS One. 2023 Dec 1;18(12):e0293046. doi: 10.1371/journal.pone.0293046. eCollection 2023.
4
Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
Viruses. 2022 Dec 6;14(12):2727. doi: 10.3390/v14122727.
5
Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.
Clin Transl Immunology. 2021 Oct 12;10(10):e1345. doi: 10.1002/cti2.1345. eCollection 2021.
6
Epidemiology of Respiratory Pathogens Among Children Hospitalized for Pneumonia in Xiamen: A Retrospective Study.
Infect Dis Ther. 2021 Sep;10(3):1567-1578. doi: 10.1007/s40121-021-00472-0. Epub 2021 Jun 19.
7
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.
Vaccines (Basel). 2020 Oct 1;8(4):574. doi: 10.3390/vaccines8040574.
8
Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.
Front Immunol. 2020 Sep 9;11:557809. doi: 10.3389/fimmu.2020.557809. eCollection 2020.
9
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20.
10
High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.
Int J Mol Sci. 2020 May 21;21(10):3643. doi: 10.3390/ijms21103643.
本文引用的文献
1
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16.
2
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
J Virol. 2005 Aug;79(15):9694-701. doi: 10.1128/JVI.79.15.9694-9701.2005.
3
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
J Immunol. 2005 Jun 1;174(11):7179-85. doi: 10.4049/jimmunol.174.11.7179.
4
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
J Virol. 2004 Dec;78(23):13207-15. doi: 10.1128/JVI.78.23.13207-13215.2004.
5
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
AIDS. 2004 May 21;18(8):1213-6. doi: 10.1097/00002030-200405210-00019.
6
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
J Immunol. 2004 May 15;172(10):6290-7. doi: 10.4049/jimmunol.172.10.6290.
7
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.
Clin Diagn Lab Immunol. 2004 Mar;11(2):351-7. doi: 10.1128/cdli.11.2.351-357.2004.
8
Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.
Annu Rev Med. 2004;55:355-72. doi: 10.1146/annurev.med.55.091902.104344.
9
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.
J Clin Microbiol. 2003 Nov;41(11):5046-52. doi: 10.1128/JCM.41.11.5046-5052.2003.
10
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.
J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003.
Zotero 插件